EGFR and non-small cell lung carcinoma: Highly expressed programmed death-ligand 1 (PD-L1) has been associated with poor clinical outcomes in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) receiving EGFR-tyrosine kinase inhibitors (TKIs).